Edward B. Garon, MD, MS

home / authors / edward-b-garon-md-ms

Articles

Key Takeaways and Closing Thoughts on ADCs

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 29th 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Emerging ADCs in Development

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 22nd 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

ADC Sequencing

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 22nd 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

Management of Emetogenicity of Antibody-Drug Conjugates

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 15th 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Managing Hematologic AEs Associated with ADC Treatments

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 15th 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

A panel of 5 experts on lung cancer seated at a long table

Clinical Pearls and Future Perspectives in Advanced NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

January 3rd 2024

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

Future Perspectives in KRAS G12C-Mutated NSCLC

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

December 28th 2023

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.

Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

December 28th 2023

Shared insight on the clinical management of hepatotoxicity with use of KRAS G12C inhibitors in mNSCLC.

Antibody-Drug Conjugates in EGFR-Mutant NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 27th 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 27th 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

December 21st 2023

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

December 21st 2023

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.

Joshua K. Sabari, MD, and Marina Chiara Garassino, MD, experts on non-small cell lung cancer

Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 20th 2023

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 20th 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 15th 2023

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 15th 2023

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Disease Progression Beyond Frontline KRAS G12C Inhibitors

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

December 14th 2023

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

December 14th 2023

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

December 7th 2023

Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.

Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

December 7th 2023

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.

A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 6th 2023

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 6th 2023

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

Frontline Treatments for KRAS G12C-Mutation mNSCLC

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

November 30th 2023

Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.

The State of Targeted Therapies in NSCLC

Joshua K. Sabari, MD;Edward B. Garon, MD, MS

November 30th 2023

Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.

EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 29th 2023

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.

Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 29th 2023

The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.

Two experts on lung cancer seated at a table

TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 22nd 2023

Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.

NSCLC: PD-L1 Expression and Treatment Decision-Making

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 22nd 2023

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

The Role of CTLA-4 Inhibitors in NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 15th 2023

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 15th 2023

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).